DiabetesMar 15, 2026
Bydureon (exenatide extended-release) can drop HbA1c by roughly 1.3 to 1.6 percentage points with a single weekly injection. That's a meaningful reduction for adults with type 2 diabetes who aren't getting enough from diet, exercise, and oral medications. But here's the tension worth understanding: head-to-head data show it's slightly less potent on both blood sugar and weight than liraglutide or semaglutide, two GLP-1 receptor agonists that now dominate the conversation.
So where does that leave Bydureon? Still effective, still convenient, but no longer the frontrunner. Whether it makes sense for you depends on what you're prioritizing and what trade-offs you're willing to accept.
InsulinMar 15, 2026
Insulin's side effect profile is narrower than many people assume. Large, long-term trials point to just three main concerns: low blood sugar, modest weight gain, and local skin reactions at injection sites. Fears about insulin causing cancer or heart disease? Not supported by high-quality trial data.
But "narrow" doesn't mean "trivial." Hypoglycemia hits roughly 20% of basal insulin users each year and is a frequent driver of hospitalizations among older adults. Knowing which side effects actually warrant your attention, and which ones you can largely stop worrying about, changes how you approach insulin therapy day to day.
DiabetesMar 15, 2026
If you have diabetes or prediabetes, you've probably seen a number called "eAG" on your lab results, sitting right next to your HbA1c. It looks helpful. It takes that somewhat abstract A1c percentage and converts it into the same units you see on your glucose meter or continuous glucose monitor (CGM). An A1c of 7%? That translates to roughly 154 mg/dL. Simple, right?
Not quite. Research shows that eAG is a useful educational shortcut, but it can be off by a meaningful amount for many individuals. For about 1 in 10 people, the gap between what eAG predicts and what their blood sugar actually averages is large enough to matter clinically. This article will help you understand what eAG is really telling you, when you can trust it, and when you should look beyond it.
DiabetesMar 15, 2026
Lantus (insulin glargine U100) doesn't actually lower your HbA1c more than the older, cheaper insulin it was designed to replace. Compared to NPH insulin, Lantus achieves similar overall blood sugar control. Where it consistently wins is in reducing nocturnal and severe hypoglycemia, the kind of lows that wake you up at 3 a.m. shaking and sweating. That distinction matters more than many people realize, because fear of nighttime lows is one of the biggest barriers to getting insulin doses where they need to be.
The other thing worth knowing upfront: multiple biosimilar versions of Lantus now exist, and the clinical data show they are highly similar in how they work, how well they work, and how safe they are. The choice between Lantus and its copies increasingly comes down to cost, which device you prefer, and how your body responds individually.
Blood SugarMar 15, 2026
Glucose tablets are a well-established treatment for low blood sugar (hypoglycemia), particularly in individuals with diabetes who take insulin or certain oral medications. These tablets deliver a precise dose of glucose, helping to restore blood sugar levels quickly and effectively. But how do they compare to other carbohydrate sources, and what does current research say about their reliability?
DiabetesMar 15, 2026
Your A1C number tells you more than whether you "have diabetes." It's a window into your risk for heart attacks, kidney failure, amputations, and death. But here's what surprises most people: danger lurks at both ends of the scale. An A1C that's too high is obviously bad, but pushing it too low can be just as risky, especially as you get older or if you have other health conditions.
The bottom line from a meta-analysis of 74 studies: for people with diabetes, A1C levels consistently at 8% or above signal clear danger, with risk climbing steeply above 9%. But for older adults or those with kidney or heart disease, even levels below 6% can increase mortality. Your ideal target isn't a single number that works for everyone.
DiabetesMar 14, 2026
Most basal insulins ask you to be precise. Same time every day, no exceptions. Tresiba (insulin degludec) breaks that pattern. In clinical studies, people injected it anywhere from 8 to 40 hours apart without losing blood sugar control or compromising safety. That kind of flexibility is rare for a basal insulin, and it comes alongside another practical benefit: lower rates of nocturnal and overall hypoglycemia compared to older options like glargine and detemir.
If you're managing type 1 or type 2 diabetes and your current basal insulin feels like a rigid obligation, Tresiba offers something worth understanding.
InsulinMar 14, 2026
Over one-third of U.S. nursing home residents with diabetes are managed on sliding scale insulin alone, a method that multiple medical societies have flagged as potentially inappropriate for long-term use. The core problem: sliding scale insulin only reacts to high blood sugar after it happens. It never prevents it. Expert reviews describe the result as a "roller coaster" glucose pattern, and the research consistently shows it leads to worse control and more hypoglycemia than alternatives.
Yet it persists. Understanding why, and when it might still make sense, matters if you or someone you care about is being managed this way in a hospital or nursing home.
DiabetesMar 13, 2026
Fiasp delivers roughly double the insulin exposure in the first 30 minutes compared to standard insulin aspart, and about 70 to 75 percent more glucose-lowering in that same early window. Those are striking pharmacology numbers. Yet when you zoom out to the metrics most people care about, like A1c and time in range, the clinical advantage shrinks to something much more modest. That gap between impressive speed and underwhelming overall results is the central story of Fiasp, and understanding it helps you figure out whether it's worth the switch.
Fiasp is not a new insulin molecule. It is the same insulin aspart with two added ingredients: niacinamide (a form of vitamin B3) to speed absorption, and L-arginine to keep the formulation stable. That simple tweak shifts the entire action profile earlier, not bigger.
DiabetesMar 13, 2026
Metformin can reduce the chance of prediabetes progressing to type 2 diabetes by roughly 25 to 30 percent. That sounds meaningful, and it is. But here's the tension: lifestyle changes like diet and exercise consistently outperform the drug, and many people with prediabetes never progress to diabetes at all. Some even revert to normal blood sugar on their own. So the real question isn't whether metformin works. It's whether it makes sense for you.
The answer depends heavily on your age, weight, blood sugar levels, and medical history. For a specific subset of people, metformin is a genuinely useful tool. For the rest, it may be an unnecessary medication for a problem that better habits can solve more effectively.
